SEC Form 4
Idexx Laboratories Inc (IDXX) insider trading
In the 12 months to Oct 23, 2026, 6 IDXX insiders reported open-market sales of $37.7M across 8 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $37.7M
- 8 filings · 6 insiders
- Open-market purchases
- $0
- 0 filings
Who traded IDXX, and when
- Sale
IDXX daily close from Oct 23, 2025 to Oct 23, 2026, between $504.70 and $766.68, last $560.38. 8 sale and 0 purchase filings by 6 insiders, marked at their filing dates. Jonathan Jay Mazelsky, President and CEO: sold $15.3M across 1 filing, first filed Mar 2, 2026, last Mar 2, 2026. Nimrata Hunt, Executive Vice President: sold $9.5M across 3 filings, first filed Nov 10, 2025, last Mar 5, 2026. George Fennell, Executive Vice President: sold $7.3M across 1 filing, first filed Feb 11, 2026, last Feb 11, 2026. Michael G. Erickson, Executive Vice President: sold $3.4M across 1 filing, first filed Feb 19, 2026, last Feb 19, 2026. Lawrence D. Kingsley, Director: sold $1.2M across 1 filing, first filed Sep 9, 2026, last Sep 9, 2026. Sophie V. Vandebroek, Director: sold $920.3K across 1 filing, first filed Feb 19, 2026, last Feb 19, 2026.
Largest mark · tap a row for others
Jonathan Jay Mazelsky · President and CEO
Sale $15,338,081
23,326 shares at $657.55 avg
Filed Mar 2, 2026 · traded Feb 26
Close on filing date $636.70
Jonathan Jay Mazelsky · President and CEO
President and CEO
$15.3M soldNimrata Hunt · Executive Vice President
Executive Vice President
$9.5M soldGeorge Fennell · Executive Vice President
Executive Vice President
$7.3M soldMichael G. Erickson · Executive Vice President
Executive Vice President
$3.4M soldLawrence D. Kingsley · Director
Director
$1.2M soldSophie V. Vandebroek · Director
Director
$920.3K soldHas Idexx Laboratories Inc's CEO sold stock?
Yes. Jonathan Jay Mazelsky (CEO) sold 23,326 shares ($15.3M) in Mar 2026.
Open-market trades
8 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Jonathan Jay Mazelsky | President and CEO | $15.3M | — | 1 | — | |
| Nimrata Hunt | Executive Vice President | $9.5M | — | 3 | — | |
| George Fennell | Executive Vice President | $7.3M | — | 1 | — | |
| Michael G. Erickson | Executive Vice President | $3.4M | — | 1 | — | |
| Lawrence D. Kingsley | Director | $1.2M | — | 1 | — | |
| Sophie V. Vandebroek | Director | $920.3K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Lawrence D. Kingsley Director | Sale | 2,203 | $532.08 | $1.2M | 9,568 | |
traded | Nimrata Hunt Executive Vice President | Sale | 1,758 | $634.57 | $1.1M | 18,141 | |
traded | Jonathan Jay Mazelsky President and CEO | Sale | 23,326 | $657.55 | $15.3M | 104,556 | |
traded | Nimrata Hunt Executive Vice President | Sale | 2,693 | $661.54 | $1.8M | 19,899 | |
traded | Sophie V. Vandebroek Director | Sale | 1,464 | $628.62 | $920.3K | 1,167 | |
traded | Michael G. Erickson Executive Vice President | Sale | 5,371 | $627.38 | $3.4M | 12,693 | |
traded | George Fennell Executive Vice President | Sale | 11,345 | $646.72 | $7.3M | 19,641 | |
traded | Nimrata Hunt Executive Vice President | Sale | 9,425 | $703.34 | $6.6M | 21,149 |
GET /stocks/filings/vX/form-4?tickers=IDXX&filing_date.gte=2025-10-23&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"IDXX"
],
"issuer_cik": "0000874716",
"owner_cik": "0001301427",
"accession_number": "0000874716-26-000127",
"form_type": "4",
"filing_date": "2026-09-09",
"period_of_report": "2026-09-04",
"issuer_name": "IDEXX LABORATORIES INC /DE",
"issuer_trading_symbol": "IDXX",
"owner_name": "Kingsley Lawrence D",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-04",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2203,
"transaction_price_per_share": 532.0826,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 9568,
"transaction_value": 1172177.9678,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents the weighted average price of the shares sold ranging from a low of $531.88 to a high of $532.14 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price."
}
]
},
{
"tickers": [
"IDXX"
],
"issuer_cik": "0000874716",
"owner_cik": "0001800619",
"accession_number": "0000874716-26-000049",
"form_type": "4",
"filing_date": "2026-03-05",
"period_of_report": "2026-03-03",
"issuer_name": "IDEXX LABORATORIES INC /DE",
"issuer_trading_symbol": "IDXX",
"owner_name": "Hunt Nimrata",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Executive Vice President",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-03-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1758,
"transaction_price_per_share": 634.5718,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 18140.944,
"transaction_value": 1115577.2244000002,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 83 records
- Option exercises67 records
- Tax withholding12 records
- Grants and awards4 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for IDXX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.